Fluoxetine 20 mg: How Lilly Opened One SSRI Shelf

The claim: a depression pill from day one

Write the rumor first. Then open who actually sat at the bench.

Most origin tales start with a disease and walk forward to a molecule. Fluoxetine's path ran the other way. In the early 1970s, Eli Lilly already sold older antidepressants. Those drugs worked on mood and also on a long receptor list - dry mouth, constipation, blurred vision, postural blood-pressure drops, weight gain, and a month's supply that could kill if swallowed at once. The Indianapolis question was not 'can we beat depression harder.' It was 'can we touch serotonin and leave the rest alone.'

Arvid Carlsson's Swedish work had already shown that serotonin reuptake could be blocked without dragging noradrenaline along. That gave Lilly a target, not a product. Ray Fuller argued the biochemical case inside the company. Bryan Molloy and Klaus Schmiegel built a phenoxyphenylpropylamine series from an antihistamine scaffold. David T. Wong ran the uptake assays. None of them could yet promise a green-and-cream capsule, a 20 mg starting dose, or a household name. The molecule came first. The indication was argued later. Full pharmacology of what they made sits in the Prozac 20 mg fact line.

The scaffold started as an antihistamine

Strike the image of a blank notebook and a sudden structure. Molloy's series grew from diphenhydramine - the same antihistamine sitting in countless night-time cold packs. Chemists already knew that family could mess with monoamine uptake. The edit was to keep the phenoxyphenylpropylamine frame and tune it until serotonin uptake fell and noradrenaline and dopamine stayed mostly upright.

That is unglamorous work. You make close cousins, you grind nerve-ending preparations, you watch which transmitter the tissue still vacuums up. Selectivity in a dish is a hypothesis. It is not a personality change and it is not a cure. Wong's group needed a compound that blocked serotonin hard and left the other two pumps relatively quiet. One entry did that. Lilly tagged it 110140. Later it wore the name fluoxetine. The chemistry was a restraint project: fewer receptors, not a louder hammer.

Wong's July 1972 assay, not a eureka speech

The date people keep quoting is 24 July 1972. Treat it as a lab day, not a statue unveiling.

Wong had joined the antidepressant project in 1971. He knew the European serotonin literature and he had a working reuptake assay. On that July day the series produced a compound that blocked serotonin uptake and barely touched the other monoamines. Fuller then ran it in chloroamphetamine-treated rats and saw the same serotonin-selective pattern. The notebook line became a candidate.

Publication lagged, as it does. In 1974 Wong, Horng, Bymaster, Hauser, and Molloy described Lilly 110140 in Life Sciences as a selective serotonin-uptake inhibitor. The paper floated two jobs: a possible antidepressant, and a research tool for people who wanted to poke serotonin without wrecking the rest of the synapse. The company named the compound fluoxetine around 1975. A test-tube win still sat more than a decade from a US pharmacy shelf. Anyone who compresses that gap into a montage is selling a film, not a file.

Fifteen years of doubt inside Lilly

The claim that Lilly always knew it had a blockbuster does not survive a 1983 Wall Street Journal quote. A company spokesperson said fluoxetine was not expected to be a major hit. Lilly still had cosmetics and devices. That is not late-stage swagger. That is a firm hedging a long, expensive, serotonin-only bet that many colleagues had mocked.

Early development wandered. Weight and blood pressure were poked before major depression locked as the filing. Animal safety, then phased human trials, then the slow proof that a once-daily capsule could beat placebo on a depression scale without handing primary-care doctors a lethal overdose kit. Enrollment does not compress because a chemist is impatient. Compound in 1972. American drugstores in early 1988. Fifteen-plus years is ordinary for a new mechanism, and the delay is the story, not a footnote. How later trials actually scored the wait is in the depression and OCD trial file.

29 December 1987, then the green-and-cream launch

Regulators stamped major depressive disorder at the end of 1987. Pharmacies saw Prozac in 1988.

The FDA cleared fluoxetine hydrochloride for major depression on 29 December 1987. Lilly launched it as Prozac - a once-daily capsule, often 20 mg in the morning, no blood-level ritual, no slow tricyclic climb for many adults. That simplicity did as much work as any HAM-D point. Family doctors, not only psychiatrists, could write it without feeling they had handed a suicidal patient a fatal month's supply.

Head-to-head, fluoxetine did not out-muscle the tricyclics on average depression scores. It matched them with a different harm profile: less anticholinergic clutter, far wider overdose margin. Usability opened the shelf. Later SSRIs walked through the door Prozac had kicked. The 20 mg strength that still sits on this site's SERP lock is not a modern marketing pick. It is the adult start the label still treats as enough for many people with major depression. A once-daily swallow without a blood-level ritual was, in 1988, a practical revolution even if the rating-scale gain was only a match.

First on the US shelf that actually stuck

Strike 'first SSRI ever made' if someone says it without a map. Zimelidine and indalpine reached European markets earlier and then left over safety problems. They never defined the class in American clinics. Fluoxetine was the first selective serotonin reuptake inhibitor on the US market and the first to sell at genuine blockbuster scale. First to last beat first to arrive.

By 1990 the capsule had outrun Lilly's modest forecast. Primary care widened the audience. Depression that once sat untreated because older drugs felt too fiddly or too dangerous now had a once-daily option a generalist might reach for. Accessibility, not a secret extra point on a rating scale, is why the SSRI shelf exists as a public fact rather than a specialty drawer. Practical start, wait, and exit live in the 20 mg weeks-and-taper card.

Culture arrived after the label, not before

Magazine covers and dinner-table arguments came in the early 1990s, after the prescribing information already existed. Peter Kramer's 1993 book asked whether some people felt 'better than well' and named the worry cosmetic pharmacology. Elizabeth Wurtzel's 1994 memoir put a young face on both the illness and the capsule. Prozac stopped being only a bottle and became a symbol argued over by people who never swallowed it.

Backlash arrived on the same clock. Overprescription, medicalized sadness, early lawsuits tying the drug to violence. Large reviews did not support the idea that fluoxetine turns ordinary adults into violent actors. A smaller, later, regulated signal - more suicidal thinking in children, teens, and young adults early in treatment - is a real boxed line, not a 1991 headline. File the culture as culture. File the boxed warning on the safety card, not in this origin note.

What the SSRI file still holds

The file keeps a team, not a lone genius. Molloy and Schmiegel made the series. Fuller pushed the serotonin case. Wong ran the assay that named 110140. Lilly then spent fifteen years proving a cleaner drug could live in ordinary clinics. Restraint - one transmitter, fewer receptors - is what made the 20 mg capsule usable by people who were not psychiatrists. That is the long shot: not a louder hammer, a narrower one that primary care would actually write.

The file also keeps the lag. A 1972 notebook line is not a 1988 bottle. Marketing, culture, and later safety language wrote chapters the chemists could not see. If you want the molecule as it sits on a US label today - half-life, indications, the wait - open the Prozac 20 mg fact line. If you want whether HAM-D and Y-BOCS actually moved, open the trial file. This page only answers how a long shot in Indianapolis opened a shelf.